Presenting research from the American College of Allergy, Asthma, and Immunology.

Adjuvant ensartinib improves disease-free survival compared to placebo following complete resection of ALK-positive non-small cell lung cancer.

Illness severity, advanced age, and chronic liver disease were strong predictors of 30-day mortality among hospitalized patients with CAP.

Omadacycline has a high clinical success rate for treating community-acquired bacterial pneumonia (CABP), according to results of a study presented at IDWeek 2025, held from October 19 to 22, in ...

The FDA has approved Kygevvi (doxecitine and doxribtimine) for the treatment of TK2d in adults and pediatric patients with an age of symptom onset on or before 12 years.

For patients with certain types of advanced lung or skin cancer, administration of SARS-CoV-2 mRNA vaccine within 100 days of starting ICIs is associated with increased overall survival.

Data from a phase 1/2 study support the use of sevabertinib in patients with HER2-mutated NSCLC, an investigator says.

Lung cancer risk is similar among women and men older that age 55 years, regardless of their smoking status, according to study findings published in Respiratory Medicine.

A 6-week individualized smoking cessation program led to greater quit rates among patients with RA when compared with usual care.

Empiric concomitant coverage of MRSA and multidrug-resistant organisms is not necessary for most patients with sepsis.

A higher oxidative balance score is associated with increased odds of allergic rhinitis in an adjusted analysis.

The FDA announced that it will relax certain rules for approving low-cost versions of some high-priced medications.